GSK GlaxoSmithKline PLC ADR

$43.44

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About GlaxoSmithKline PLC ADR

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Website: https://www.gsk.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1131399
Address
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX, GB
Valuation
Market Cap
$72.79B
P/E Ratio
21.78
PEG Ratio
0.35
Price to Book
4.03
Performance
EPS
$1.65
Dividend Yield
4.33%
Profit Margin
8.21%
ROE
22.80%
Technicals
50D MA
$37.51
200D MA
$37.73
52W High
$44.37
52W Low
$31.37
Fundamentals
Shares Outstanding
2B
Target Price
$42.87
Beta
0.30

GSK EPS Estimates vs Actual

● Estimated
● Actual

GSK News & Sentiment

Sep 30, 2025 • Benzinga NEUTRAL
AnaptysBio Charts Path To Split Into Two Companies By 2026 - AnaptysBio ( NASDAQ:ANAB )
AnaptysBio, Inc. ( NASDAQ:ANAB ) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.
Sep 29, 2025 • Benzinga NEUTRAL
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026 - GSK ( NYSE:GSK )
GSK plc ( NYSE: GSK ) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Walmsley.
Sep 26, 2025 • Benzinga SOMEWHAT-BULLISH
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Amgen ( NASDAQ:AMGN )
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc ( NASDAQ: AMGN ) announced a $650 million expansion of its U.S. manufacturing network.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Sep 19, 2025 • Benzinga NEUTRAL
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' - Dynavax Technologies ( NASDAQ:DVAX ) , GSK ( NYSE:GSK )
Sen. Elizabeth Warren ( D-Mass. ) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Sentiment Snapshot

Average Sentiment Score:

0.112
50 articles with scored sentiment

Overall Sentiment:

Neutral

GSK Reported Earnings

Feb 05, 2025
Dec 31, 2024 (Pre market)
0.09 Surprise
  • Reported EPS: $0.58
  • Estimate: $0.49
  • Whisper: —
  • Surprise %: 18.8%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $1.29
  • Estimate: $1.23
  • Whisper: —
  • Surprise %: 4.9%
Jul 31, 2024
Jun 30, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $1.10
  • Estimate: $0.99
  • Whisper: —
  • Surprise %: 11.1%
May 01, 2024
Mar 31, 2024 (Pre market)
0.18 Surprise
  • Reported EPS: $1.09
  • Estimate: $0.91
  • Whisper: —
  • Surprise %: 19.8%
Jan 31, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $0.72
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: -5.3%
Nov 01, 2023
Sep 30, 2023 (Pre market)
0.14 Surprise
  • Reported EPS: $1.28
  • Estimate: $1.14
  • Whisper: —
  • Surprise %: 12.3%
Jul 26, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $0.97
  • Estimate: $0.87
  • Whisper: —
  • Surprise %: 11.5%
Apr 26, 2023
Mar 31, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $0.90
  • Estimate: $0.82
  • Whisper: —
  • Surprise %: 9.8%
Feb 01, 2023
Dec 31, 2022 (Pre market)
0.11 Surprise
  • Reported EPS: $0.61
  • Estimate: $0.50
  • Whisper: —
  • Surprise %: 22.0%

Financials